(Q39138335)

9 September 2017

Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor (English)

1 reference

9 September 2017

1 reference

1 reference

Masaki Shiota

1

1 reference

9 September 2017

Eiji Kashiwagi

2

1 reference

9 September 2017

Akira Yokomizo

3

1 reference

9 September 2017

Ario Takeuchi

4

1 reference

9 September 2017

Takashi Dejima

5

1 reference

9 September 2017

Yoohyun Song

6

1 reference

9 September 2017

Katsunori Tatsugami

7

1 reference

9 September 2017

Junichi Inokuchi

8

1 reference

9 September 2017

Takeshi Uchiumi

9

1 reference

9 September 2017

Seiji Naito

10

1 reference

9 September 2017

14 June 2013

1 reference

9 September 2017

1 reference

9 September 2017

73

1 reference

9 September 2017

12

1 reference

9 September 2017

1336-1344

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

9 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Novel therapeutic strategies following docetaxel-based chemotherapy in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Identification of docetaxel resistance genes in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Increased expression of class III beta-tubulin in castration-resistant human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Y-box binding protein-1 mediates profibrotic effects of calcineurin inhibitors in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Androgen-induced up-regulation of tubulin isoforms in neuroblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22681

21 January 2018

Identifiers

DOI

10.1002/PROS.22681

1 reference

9 September 2017

1 reference